Troy Healthcare’s latest product, Stopain® Clinical Migraine & Headache, is formulated to provide immediate and safe pain relief for the estimated 39 million individuals suffering from migraines in the United States alone.

The topical treatment does not include acetaminophen, aspirin, caffeine or other NSAIDs and offers an effective alternative to potentially addictive opioids. The launch of the product comes at a time where frequency of migraines is on the rise due to increased stress from pandemic related economic hardships and COVID-19 associated headaches.

Troy Healthcare is known for its topical analgesic products, Stopain® Clinical, that offer a professional level of relief for those suffering from arthritis, chronic pain, back aches or sprains. Physical therapists, chiropractors, massage therapists, athletic trainers, and other health care professionals rely on Stopain® Clinical to help their patients control pain.

On the heels of Stopain® Clinical’s success with the topical analgesic line, the company developed a new formula that offers a respite to the millions suffering from migraines and headaches. The active ingredients of Stopain® Clinical Migraine & Headache are effective in reducing the incapacitating symptoms typically associated with migraines; including pain in the front and back of the head, as well as, controlling nausea and sickness.

“We’re excited to offer this product to the market,” says Anthony Cicini, president of Troy Healthcare, LLC. “With consumers becoming more aware of the negative long-term effects of the ingestible medication they’re using, we’re proud to offer a topical solution that is safe and effective in relieving migraines and headaches during any stage of progression. Being able to use this product multiple times per day and in conjunction with other pain-relieving products has been a huge benefit for migraine and severe headache sufferers.”

Individuals suffering from migraines know that relief can be difficult to achieve. A study conducted at Thomas Jefferson Headache Center showed a significant improvement in headache intensity within two hours of application. The study also concluded that after two hours, 52% of participants saw significant improvement by at least one severity level and 32% had no additional pain progression.

The director at the Jefferson Headache Center, Dr. Stephen Silberstein, determined in his conclusion statement that the product “is safe and effective in the treatment of an acute migraine attack.” (Thomas Jefferson Headache Center, 2012)

“I felt relief within minutes of applying Stopain® Clinical Migraine & Headache to the back of my neck during a recent migraine episode,” said John Stefanik, a Stopain® Clinical Migraine & Headache user. “Typically, when I experience a migraine my only option is to lay in a dark room and wait for symptoms to subside. With Stopain® Clinical Migraine & Headache, the pain in the back of my neck and front of my head subsided and I was able to continue my work day.”

Stopain® Clinical Migraine & Headache is sold exclusively through health care professionals. Check with your local hands-on health care professional for purchase information. You can also use the Stopain® Clinical zip code locator to find a health care facility offering Stopain® Clinical Migraine & Headache near you.

About Troy Healthcare, LLC
Troy Healthcare, LLC owns and manufactures 100% of the process for all of its products, ensuring the highest level of quality. Subsidiaries of Troy Healthcare include Stopain® Clinical and Stopain® Clinical Migraine & Headache. All of the company’s research, quality standards and business practices are managed according to FDA guidelines. For over 20 years, Troy Healthcare has been manufacturing topical analgesics in the USA at their Pennsylvania based facility. For more info go to

The post Troy Healthcare debuts clinically-validated topical migraine and headache formula appeared first on Chiropractic Economics.

By: Chiropractic Economics
Title: Troy Healthcare debuts clinically-validated topical migraine and headache formula
Sourced From:
Published Date: Fri, 22 Jan 2021 14:47:48 +0000